Phaseline

Targets › CDKN1A

CDKN1A (Cyclin-dependent kinase inhibitor 1): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Oncology; next expected readout May 2027.

Plays an important role in controlling cell cycle progression and DNA damage-induced G2 arrest. Involved in p53/TP53 mediated inhibition of cellular proliferation in response to DNA damage. (UniProt, P38936)

Open in Phaseline: the race on CDKN1A, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
UNICANCERHIPEC (Hyperthermic Intra-Peritoneal Chemotherapy with cisplatin)
Hyperthermic intra-peritoneal chemotherapy delivering cisplatin directly to peritoneal cav
CDKN1APhase 3Ovarian Epithelial Cancer RecurrentMay 2027

Conditions

Ovarian Epithelial Cancer Recurrent (1)

Modalities

small molecule (1)

Companies

UNICANCER (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.